As we have previously reported, the use of Pradaxa has been linked to serious injury. There are nearly 600 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.
Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, recently signed Case Management Order 48. Judge Herndon ordered the parties to “designate up to three cases for inclusion as an early trial case” by December 16, 2013. The Court will select four cases for trial by January 23, 2014. The current trial dates for these cases are set for February 16, 2014; August 11, 2014; November 3, 2014 and January 5, 2015.
If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.